Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 1, 2003, Pages 57-63

  Kurnik, D ^a,b   Loebstein, R ^a,b   Fishbein, E ^a,b   Almog, S ^a,b   Halkin, H ^a,b   Bar Meir, S ^a,b   Chowers, Y ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; INFLIXIMAB; METHOTREXATE; STEROID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CROHN DISEASE; CROSSOVER PROCEDURE; DOSE CALCULATION; DRUG BIOAVAILABILITY; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; ISRAEL; MALE; PRIORITY JOURNAL; RANDOMIZATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL AVAILABILITY; CROHN DISEASE; CROSS-OVER STUDIES; DRUG COMBINATIONS; FEMALE; FOLIC ACID; HALF-LIFE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED;

EID: 0041843894     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01614.x     Document Type: Article

References (32)

1. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353-6.
2. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332: 292-7.
3. Feagan BG, Fedorak RN, Irving EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 2000; 342: 1627-32.
4. Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther 2001; 15: 35-44.
5. Lémann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000; 95: 1730-4.
6. Fraser AG, Morton D, McGovern D, et al. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 693-7.
7. Vandell AG, DiPiro JT. Low-dose methotrexate for treatment and maintenance of remission in patients with inflammatory bowel disease. Pharmacotherapy 2002; 22: 613-20.
8. Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic-active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997; 92: 2203-9.
9. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind placebo-controlled trial. Hepatogastroenterology 1999; 46: 1724-9.
10. Oguey D, Kolliker F, Gerber NJ, et al. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 611-4.
11. Jundt JW, Browne BA, Fiocco GP, et al. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20: 1845-9.
12. Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36: 89-90.
13. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med 1994; 121: 833-41.
14. Kozarek RA. Methotrexate for refractory Crohn's disease: preliminary answers to definite questions. Mayo Clin Proc 1996; 71: 104-5.
15. Sierra EE, Goldman ID. Recent advances in the understanding of the mechanism of membrane transport of folate and antifolates. Semin Oncol 1999; 26(S6): 11-23.
16. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002; 122: 512-30.
17. Pesce MA, Bodourian DH. Evaluation of fluorescence polarization immunoassay procedure for quantitation of methotrexate. Ther Drug Monit 1986; 8: 115-21.
18. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications, 3rd edn. Philadelphia: Williams & Wilkins, 1995.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
20. Bannwarth B, Pehourcq F, Schaeverbeke T, et al. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996; 30: 194-210.
21. Edelman J, Biggs DF, Fakhreddin J, et al. Low-dose methotrexate kinetics in arthritis. Clin Pharmacol Ther 1984; 35: 382-6.
22. Brooks PJ, Spruill WJ, Parish RC, et al. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 91-4.
23. Kremer JM, Petrillo GF, Hamilton RA. Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months. J Rheumatol 1995; 22: 41-4.
24. Godfrey C, Sweeney K, Miller K, et al. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol 1998; 46: 369-76.
25. Hamilton RA, Kremer JM. The effects of food on methotrexate absorption. J Rheumatol 1995; 22: 630-2.
26. Herman RA, Veng-Pedersen P, Hoffman J, et al. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci 1989; 78: 165-71.
27. Moshkowitz M, Oren R, Tishler M, et al. The absorption of low-dose methotrexate in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1997; 11: 569-73.
28. Crom WR, Evans WE. Methotrexate. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics, Principles of Therapeutic Drug Monitoring, 3rd edn. Vancouver, Washington: Applied Therapeutics, Inc., 1992: 29-1-42.
29. Zeng H, Chen ZS, Belinsky MG, et al. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res 2001; 61: 7225-32.
30. Lebbe C, Beyeler C, Gerber NJ, et al. Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 475-7.
31. Chladek J, Grim J, Martinkova J, et al. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol 2002; 54: 147-56.
32. Eksborg S, Albertioni F, Beck O, et al. Methotrexate in rheumatoid arthritis - a limited sampling strategy for estimation of the area under the plasma concentration versus time curve. Ther Drug Monit 1994; 16: 560-3.